Alivus Life Sciences Q1 FY27 Results: Non-GPL Growth Drives Margins as GPL Business Declines
Alivus Life Sciences Limited reported its financial results for the first quarter of Fiscal Year 2027, highlighting strong growth in the non-Generic API (non-GPL) segment despite a significant de-growth in the GPL business. The company generated a strong free cash flow and expressed confidence in achieving targeted revenue growth for the full fiscal year FY27.The Q1 FY27 results demonstrated operational efficiencies across the company. Revenue from operations stood at ₹6,404 million. EBITDA for the quarter was ₹2,341 million, translating to an EBITDA margin of 36.6%. The company recorded a Profit After Tax (PAT) of ₹1,601 million, achieving a net margin of 25.0%.
The performance breakdown is detailed in the table below:
| Particulars (In ₹ Million) | Q1 FY27 | Q4 FY26 | QoQ Change | Q1 FY26 | YoY Change |
|---|---|---|---|---|---|
| Revenue from Operations | 6,404 | 6,891 | -7.1% | 6,018 | 6.4% |
| Gross Profit | 3,854 | 4,182 | -7.8% | 3,315 | 16.3% |
| EBITDA | 2,341 | 2,373 | -1.3% | 1,813 | 29.1% |
| EBITDA Margin (%) | 36.6% | 34.4% | +220 bps | 30.1% | +650 bps |
| PAT | 1,601 | 1,627 | -1.6% | 1,215 | 31.8% |
| Net Margin (%) | 25.0% | 23.6% | +140 bps | 20.2% | +480 bps |
Segmental Performance Highlights
The company noted that its business model showed resilience, driven by the non-GPL portfolio. The non-GPL business recorded a substantial growth rate of 27.6% Quarter-on-Quarter (QoQ) and 26.5% Year-on-Year (YoY). This momentum was attributed to healthy demand across all geographies and effective execution, supported by new product launches. Gross Margins for the quarter were at 60.2%, reflecting a 510 basis points (bps) increase on the back of favorable product mix.In contrast, the GPL business witnessed a de-growth of 52.6% YoY due to inventory rationalization. Management anticipates that the GPL business is expected to be flattish for the full year FY27, although recovery was expected in H2FY27.
The CDMO business showed a growth of 3.8% YoY in Q1FY27, with management noting that contributions from both new and existing projects are expected to translate into better growth in H2FY27. Meanwhile, generic API revenues grew by 7.4% YoY.
Financial Health and Operational Metrics
The company generated a strong free cash flow of ₹901 million, leading to Cash and Cash Equivalents (including short-term investments) totaling ₹8,802 million as of June 30, 2026. Other indicators showed that ROICE was tracking at approximately 32%, and the company maintains a robust balance sheet.Management stated confidence in achieving revenue growth between 10% and 12% for FY27 while sustaining EBITDA margins within the 30% to 32% range, guided by strong non-GPL momentum.
R&D Capabilities and Global Footprint
Alivus continues to expand its technological base and regulatory filings globally. The company has filed a total of 617 DMFs and CEPs across major markets, including the United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China, and Australia.In terms of research and development (R&D), the Health Promotion (HP) API portfolio is actively progressing, featuring 29 products in the active development grid. Of these, 13 products have been validated, seven are in advanced stages of development, and nine are moving through lab development. The iron complexes portfolio has also advanced, with one compound's regulatory filing completed, one product validated, and another proceeding through advanced development.
Future Capacity Expansion Plans
The company is making strategic investments to bolster its future manufacturing capacity and R&D infrastructure. Construction has commenced for a new R&D facility in Taloja (Navi Mumbai), which will focus on flow chemistry, complex products, particle engineering, oncology research, and green chemistry.A multi-phase expansion plan has been laid out for API production:
| Expansion Type | Division | Location | Operational Timelines |
|---|---|---|---|
| Brownfield (API / Intermediate) | API / Intermediate | Ankleshwar | Planned addition of ~100KL Capacity in Q4 FY27 |
| Brownfield (API) | API | Dahej | Planned addition of ~160KL Capacity in Q3 FY27 |
| Greenfield (API/Intermediate) | API / Intermediate | Solapur | Phase 1: ~350 KL (Q3 FY27); Phase 2: ~115 KL (Q4 FY27); Phase 3: ~535 KL (FY29) |
ALIVUS Stock Price Movement
Shares of Alivus Life Sciences Limited today slipped by 0.41% to close at ₹1,095.70 after trading in the post-market session. The stock saw a traded volume of 53,239 shares during the day.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: